Dear Editor,Interleukin (IL)-17 inhibitors have significantly advancedthe treatment of moderate-to-severe psoriasis. However,paradoxical eczema is emerging as a treatment-relatedcutaneous adverse event, presenting both diagnostic andtherapeutic challenges.
Management of IL‐17 inhibitors‐induced paradoxical eczema in patients with plaque psoriasis
Paolo Gisondi;Francesco Bellinato
2026-01-01
Abstract
Dear Editor,Interleukin (IL)-17 inhibitors have significantly advancedthe treatment of moderate-to-severe psoriasis. However,paradoxical eczema is emerging as a treatment-relatedcutaneous adverse event, presenting both diagnostic andtherapeutic challenges.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Acad Dermatol Venereol - 2025 - Gisondi - Management of IL‐17 inhibitors‐induced paradoxical eczema in patients with plaque.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
336.41 kB
Formato
Adobe PDF
|
336.41 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
